Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ix Therapeutics
Hamburg, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
Ix Therapeutics is in early drug development with no reported clinical results; focuses on discovering novel targets and developing functional antibodies for colorectal and lung cancer using AI-driven platforms and Veraxa's Droplet Microfluidic technology.[1][2]
- Therapeutic areas
- Oncology
- Modalities
- Functional antibodies
- Industry
- Biotech
02
Partnerships
Veraxa Biotech AG (antibody development)Indivumed GmbH (joint venture parent)Xlife Sciences AG (joint venture partner)
Beyond the preview
Go deeper on Ix Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ix Therapeutics.